Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

382
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
382
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

391
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
391
Tissue Transplantation01:24

Tissue Transplantation

804
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
804
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Transcytosis of IgG01:15

Transcytosis of IgG

3.9K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "3D-printed alginate/gelatin/platelet-rich plasma composite scaffold with magnesium-containing bioactive glass for enhancing the chondrogenic differentiation of mesenchymal stem cells in cartilage tissue engineering" [Int. J. Biol. Macromol. 361 (2026) 151968].

International journal of biological macromolecules·2026
Same author

Association of HLA alleles and mismatches with post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review and meta-analysis.

Transplant immunology·2026
Same author

Association of interleukin-8 and neutrophil-to-lymphocyte ratio with clinical indices in diabetic nephropathy.

Caspian journal of internal medicine·2026
Same author

3D-printed alginate/gelatin/ platelet-rich plasma composite scaffold with magnesium-containing bioactive glass for enhancing the chondrogenic differentiation of mesenchymal stem cells in cartilage tissue engineering.

International journal of biological macromolecules·2026
Same author

Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption.

Biomaterials advances·2026
Same author

Optimized gradient of lyophilized platelet-rich plasma in biomimetic 3D-printed triphasic scaffold based on alginate and gelatin for osteochondral tissue engineering.

Scientific reports·2026

Related Experiment Video

Updated: Dec 24, 2025

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.5K

Tocilizumab in transplantation.

Banafsheh Mosharmovahed1, Yousef Fatahi2,3, Bahareh Mohebbi4

  • 1Department of chemical engineering-pharmaceutical engineering, University of Tehran, Tehran, Iran.

European Journal of Clinical Pharmacology
|April 9, 2020
PubMed
Summary
This summary is machine-generated.

Tocilizumab, an IL-6 receptor blocker, shows promise in promoting graft survival in transplantation. However, its use requires further definition due to potential increased infection rates.

Keywords:
Allograft rejectionGraft versus host diseaseIL-6Stem cell transplantationTocilizumabTransplantation

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.3K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.8K

Related Experiment Videos

Last Updated: Dec 24, 2025

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.5K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.3K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.8K

Area of Science:

  • Immunology
  • Transplantation Medicine

Background:

  • Interleukin-6 (IL-6) significantly contributes to adverse outcomes in transplantation, including cytokine storm, graft-versus-host disease, and solid organ allograft rejection.
  • Tocilizumab targets the IL-6 receptor, potentially mitigating these detrimental IL-6 effects.

Purpose of the Study:

  • To summarize the clinical consequences of blocking IL-6 with tocilizumab in stem cell and solid organ transplantations.
  • To evaluate tocilizumab's potential in promoting graft survival and facilitating tolerance induction.

Main Methods:

  • Comprehensive literature search using PubMed, SCOPUS, and Google Scholar.
  • Keywords derived from PubMed MeSH, with no time or article type limitations.

Main Results:

  • Tocilizumab demonstrates potential in controlling both cellular and humoral immunity, suggesting promise for tolerance induction.
  • A key concern is the potential for an augmented infection rate in recipients due to IL-6 pathway blockade.

Conclusions:

  • Tocilizumab is a promising agent for transplantation, but its application requires further research to define optimal use.
  • Balancing the benefits of IL-6 inhibition with the risk of infection is crucial for safe and effective immunosuppression.